Press release content from Globe Newswire. The AP news staff was not involved in its creation. Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin Athenex, Inc.February 18, 2021 GMT Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapore, and Malaysia Athenex’s Existing Partners Include Almirall, S.A., in the United States, Europe, and Russia; and Guangzhou Xiangxue Pharmaceutical in China Almirall launches Klisyri® for actinic keratosis in the U.S. today